Sentinel lymph node biopsy for melanoma involves systematic identification and removal of the first lymph node(s) to which tumor cells would logically drain, enabling accurate pathologic staging and identification of occult metastases in 5-10% of intermediate-thickness melanomas. SLN status is strongest independent prognostic factor after Breslow thickness, substantially influencing treatment recommendations and surveillance intensity. The procedure involves preoperative lymphatic mapping with radioisotope and/or vital dye injection, intraoperative SLN identification and removal, and meticulous pathologic assessment including serial sectioning and immunohistochemistry to detect micrometastases. Understanding SLN techniques, indications, prognostic significance, and management implications enables appropriate patient selection and optimization of outcomes.

Indications and Patient Selection

Standard Indications: SLN biopsy is recommended for intermediate-thickness melanomas (1-4 mm Breslow thickness). Thin melanomas (<1 mm) have low nodal metastasis risk (<5%); however, high-risk features (ulceration, mitotic rate ≥1/mm², level IV-V, patient age <40 years) may warrant SLN consideration. Thick melanomas (>4 mm) have high nodal metastasis risk (30-50%); some argue SLN offers less incremental staging value since many patients warrant completion lymph node dissection regardless of SLN status.

Relative Contraindications: Pregnancy (radioactive tracer and anesthesia risks; can defer until postpartum). Prior lymph node dissection or radiation to relevant basin may make SLN identification difficult. Patients with in-transit metastases typically have positive SLN and may not require formal SLN biopsy given advanced stage.

Technical Approach and Mapping

Preoperative Lymphatic Mapping: Intradermal injection of technetium-99m sulfur colloid (radioisotope) and/or isosulfan blue (vital dye) around tumor site. Lymphoscintigraphy images (taken 5-20 minutes post-injection) identify sentinel lymph node basin(s). Patients are brought to operating room with knowledge of SLN location from imaging.

Intraoperative Identification: Handheld gamma probe localizes radioactivity hotspots corresponding to SLNs. Vital dye staining (blue coloration) confirms lymph node identity. Typically 1-3 SLNs are identified; all are removed.

Pathologic Processing: Critical pathologic assessment includes: (1) multiple levels (10-20 sections per node); (2) immunohistochemistry (S100, Melan-A, SOX10) enhancing detection of small metastatic foci; and (3) careful measurement of largest metastatic deposit.

Prognostic Significance

SLN-Negative Status: Indicates absence of detectable metastases in regional basin. 5-year survival for node-negative melanoma: stage I >90%; stage II 70-90% depending on primary tumor characteristics.

SLN-Positive Status: Indicates stage III disease (any primary tumor with positive SLN). 5-year survival: stage IIIA (1 micrometastasis) 78%; stage IIIB (>1 node or larger deposit) 59%; stage IIIC (4+ nodes) 40%. Metastasis size influences prognosis: micrometastases (<0.1 mm) show better outcomes than macroscopic (≥0.1 mm) disease. Extranodal extension also worsens prognosis.

Sentinel Lymph Node Biopsy Alone vs. Completion Dissection: Observation after positive SLN biopsy (without completion dissection) is increasingly employed, particularly for limited nodal disease. Completion dissection is performed for: (1) clinically obvious nodal disease; (2) extensive SLN metastases; or (3) patient preference.

Adjuvant Therapy Based on SLN Status

Node-Negative Melanoma: Stage I-II melanomas (SLN-negative) typically receive surgery alone. Adjuvant systemic therapy is not routinely recommended unless other high-risk features (very thick, large tumor burden) are present.

Node-Positive Melanoma: Stage III (SLN-positive) melanomas warrant consideration of adjuvant systemic therapy. Checkpoint inhibitors (nivolumab, pembrolizumab) or targeted therapy (for BRAF-mutant) reduce recurrence risk by 50-70% and improve overall survival by 10-20% compared to observation alone.

FAQ

Q: Why do I need sentinel lymph node biopsy?
A: SLN identifies occult nodal metastases (5-10% of patients), upstaging them to stage III and guiding adjuvant therapy decisions. It is the most accurate method for regional node staging.

Q: Is SLN biopsy necessary for all melanomas?
A: Recommended for melanomas 1-4 mm thick. Thin (<1 mm) and very thick (>4 mm) melanomas have variable indications based on additional risk factors.

Q: What happens if my SLN is positive?
A: Upstaged to stage III. Adjuvant systemic therapy (checkpoint inhibitors or targeted therapy) is typically recommended to improve survival.

Q: Will I have a scar from SLN biopsy?
A: Small incision is made over SLN; resulting scar is typically minimal (<1 cm) and cosmetically acceptable.

References

  1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer 8th edition staging system. CA Cancer J Clin. 2017;67(6):472-492.
  2. Wong SL, Kattan MW, McMasters KM, et al. Sentinel lymph node biopsy for melanoma: prognostic value of staging the extent of lymph node involvement. Arch Surg. 2004;139(7):740-746.
  3. Scolyer RA, Murali R, McCarthy SW, et al. Histologically negative sentinel lymph nodes in melanoma patients with regional metastases: a further argument for the sentinel lymph node biopsy. Ann Surg Oncol. 2007;14(10):2815-2824.
  4. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317.
  5. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3632.
  6. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86(4):212-223.
  7. Cormier JN, Xing Y, Ding M, et al. Ethnicity and surgical treatment in melanoma. J Clin Oncol. 2006;24(12):1947-1955.
  8. Slingluff CL Jr. Melanoma vaccines: lessons learned from clinical trials. Curr Opin Oncol. 2011;23(2):188-196.
  9. Bilimoria SY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection of sentinel lymph node biopsy in melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2007;14(6):1925-1933.
  10. Scoggins CR, Ross MI, Reintgen DS, et al. Sentinel lymph node biopsy in high-risk melanoma patients may guide adjuvant therapy selection. Cancer. 2006;107(10):2326-2335.